ABSTRACT
Introduction
Hypertension is one of the most common diseases in the world. Its origin dates back to 2600 BC when the ancient Chinese could only suspect hypertension by the quality of one's pulse and called it hard pulse disease & venesection & bleeding were recommended as the sole means of detecting hypertension. [1] The term "essentielle hypertonie", i.e. essential hypertension, was first quoted by the German physician Frank E in 1911 and continues to be used today. [2] It is defined as sustained increase in blood pressure ≥ 140/90 mmHg, a criterion that characterizes a group of patients whose risk of hypertension related cardiovascular disease is high enough to merit medical attention. [3] It is associated with marked morbidity, mortality & places a high burden on health care system. The risk of both macrovascular & microvascular complications including stroke, coronary artery disease, peripheral vascular disease, retinopathy, nephropathy & possibly neuropathy increases with hypertension. [4] A decrease of 2mmHg in BP can prevent 151,000 stroke and 153,000 coronary heart disease deaths in India. [5] As per the World Health Statistics 2012, of the estimated 57 million global deaths in 2008, 36 million (63%) were due to non communicable diseases (NCDs). The largest proportion of NCD deaths is caused by cardiovascular diseases (48%). It is seen frequently in individuals aged 40 years and also affects about half of population aged 60 years and above. [6] In terms of attributable deaths, raised blood pressure is one of the leading behavioural and physiological risk factor to which 13% of global deaths are attributed. Nearly 1 billion adults had hypertension in 2000 & this is predicted to increase to 1.56 billion by 2025. [7] Pooled epidemiological studies show that the average prevalence of hypertension in India is 25% in urban and 10% in rural population. [8] Treatment of hypertension Healthy life style is mandatory. [11] It is a pro-drug that is rapidly hydrolyzed into Olmesartan & absorbed from the gastrointestinal tract into the body. The peak plasma concentration reaches in 1to 2 hrs. Oral bioavailability is not affected by food.
Telmisartan angiotensin receptor blocker (ARB) shows high affinity for the angiotensin II type 1 (AT1) receptors. In addition to blocking these receptors, it acts as a selective modulator of peroxisome proliferator-activated receptor gamma (PPAR-γ), a central regulator of insulin and glucose metabolism. [12] Peak plasma levels are obtained 0. 
Discussion
Hypertension is a major contributor to cardiovascular disease and a leading cause of stroke, myocardial infarction, heart failure and kidney disease. Although benefits of blood pressure reduction have been well documented, the majority of patients remain undertreated and poorly controlled. Since hypertension is a chronic condition it is mandatory to ensure proper patient compliance to antihypertensive therapy. Medication costs, side effects of the drugs, poor quality of life are some of the main factors contributing to poor patient compliance. [13] in 2004 conducted a study,patients were randomized to Olmesartan (2.5-80 mg) or placebo once daily. It was found that Olmesartan produced a dose dependent decrease in diastolic & systolic blood pressures as compared to placebo which is consistent with our study. Nakayama et al [14] in 2007conducted a study to compare the effects of Olmesartan and Telmisartan on blood pressure, & concluded that Olmesartan lowered mean systolic and diastolic blood pressure more significantly than did Telmisartan which is also consistent with our study. In Jadhav et al [15] study Patients were randomized to either olmesartan or telmisartan monotherapy, Olmesartan showed a Significant lowering of average 24hrs SBP as compared to telmisartan which is also consistent with our study Sasaki et al [16] evaluated the effects of telmisartan and olmesartan &concluded that telmisartan is more beneficial than olmesartan in reducing blood pressure in the early morning in patients with hypertension which is not consistent with our study. Arao et al [17] conducted a crossover study in hypertensive patients with type 2 diabetes, & concluded that there is no significant difference in blood pressure reduction rate between Olmesartan & Telmisartan treatment groups. This is also not consistent with our study.
COST EFFECTIVENESS
Difference in cost of treatment of both the groups was Rs134.40±4.48. Difference in the effectiveness in reduction of BP of both the group was 0.655± 0.06. ICER value comes out to be Rs 218.35 .Telmisartan was found to be cost effective. There was no study published that compares costeffectiveness of Olmesartan & Telmisartan. But Borsema et al [18] conducted a study to evaluate cost effectiveness, showed that treatment with olmesartan versus losartan, valsartan, and irbesartan resulted in a significantly larger decrease in BP (11.5 vs 8.2, 7.9and 9.9 mmHg [p < 0.05], respectively) and consequently more complications averted.
Cost effectiveness for olmesartan, losartan, valsartan, and irbesartanwas estimated at euro 39100, euro77100, euro70700, and euro50,900 percardiovascular complication averted, respectively. The incremental cost effectiveness analysis indicated the most favorable cost-effectivenes soutcome for olmesartan, with lower costs and less cardiovascular complications for olmesartan compared with the other three ARBs. Both Olmesartan and Telmisartan effectively lowered systolic and diastolic blood pressure in supine and sitting positions, Olmesartan lowers Blood pressure more than Telmisartan. Taking into account cost Telmisartan is more cost effective. The limitation of our study was that sample size is less & can be increased to increase reliability and blinding can be done.
